

Department of Origin: Integrated Healthcare Services	Effective Date: 06/05/24
Approved by: Medical Policy Quality Management Subcommittee	Date Approved: 06/04/24
Clinical Policy Document: Neurostimulation, Hypoglossal Nerve	Replaces Effective Clinical Policy Dated: 12/12/23
Reference #: MC/I012	Page: 1 of 6

PURPOSE:

The intent of this clinical policy is to ensure services are medically necessary.

Please refer to the member’s benefit document for specific information. To the extent there is any inconsistency between this policy and the terms of the member’s benefit plan or certificate of coverage, the terms of the member’s benefit plan document will govern.

POLICY:

Benefits must be available for health care services. Health care services must be ordered by a provider. Health care services must be medically necessary, applicable conservative treatments must have been tried, and the most cost-effective alternative must be requested for coverage consideration.

GUIDELINES:

Medical Necessity Criteria – Requests for hypoglossal nerve stimulation with the use of an FDA-approved device (eg, Inspire) for the specific indication - Must satisfy any of the following: I or II

- I. Initial placement - must satisfy any of the following: A or B
 - A. The member is greater than or equal to 13 years of age and less than or equal to 17 years of age – must satisfy all of the following: 1 – 5
 - 1. The member has a diagnosis of Down Syndrome; and
 - 2. Presence of obstructive sleep *apnea* (OSA) with an *AHI/RDI/REI* score of greater than or equal to 10 and less than or equal to 50 events per hour; and
 - 3. Absence of complete concentric velopharyngeal collapse on screening sleep endoscopy; and
 - 4. Documentation of failure of or contraindication to adenotonsillectomy; and
 - 5. Failure or intolerance of positive airway pressure treatments – any of the following: a or b
 - a. PAP failure is defined as an inability to eliminate OSA (*AHI* of greater than 15 despite PAP usage); or
 - b. PAP intolerance is defined as either of the following – 1) or 2)
 - 1) Inability to use PAP (greater than 5 nights per week of usage [usage defined as greater than 4 hours of use per night]); or
 - 2) Unwillingness to use PAP (eg, a patient returns the PAP system after attempting to use it)
 - B. The member is greater than or equal to 18 years of age – must satisfy all of the following: 1 - 5
 - 1. The member has a BMI less than or equal to 40kg/m²; and
 - 2. Presence of obstructive sleep *apnea* (OSA) with an *AHI/RDI/REI* score of greater than or equal to 15 and less than or equal to 100 events per hour; and
 - 3. Presence of predominantly obstructive events (central and mixed *apneas* less than or equal to 25% of *AHI*); and

Department of Origin: Integrated Healthcare Services	Effective Date: 06/05/24
Approved by: Medical Policy Quality Management Subcommittee	Date Approved: 06/04/24
Clinical Policy Document: Neurostimulation, Hypoglossal Nerve	Replaces Effective Clinical Policy Dated: 12/12/23
Reference #: MC/I012	Page: 2 of 6

4. Failure or intolerance of positive airway pressure (PAP, CPAP) treatments – any of the following: a or b
 - a. PAP failure is defined as an inability to eliminate OSA (AHI of greater than 15 despite PAP usage); or
 - b. PAP intolerance is defined as either of the following – i or ii
 - i. Inability to use PAP (greater than 5 nights per week of usage [usage defined as greater than 4 hours of use per night]); or
 - ii. Unwillingness to use PAP (eg, a patient returns the PAP system after attempting to use it)
 5. Absence of complete concentric velopharyngeal collapse on screening sleep endoscopy.
- II. Replacement or revision of stimulator generator/battery, lead or electrode, or patient programmer (controller) – must satisfy the following: A, and B or C, as applicable
- A. The indication for initial placement meets indications under I.; and
 - B. Request is for replacement of the existing generator/battery or patient programmer (controller) – must satisfy any of the following: 1 - 2
 1. The battery life is less than 1 year; or
 2. The device must be *malfunctioning* and no longer under warranty.
 - C. Request is for replacement and/or revision of lead/electrode due to migration and/or no longer functioning properly is considered medically necessary.

EXCLUSIONS (not limited to):

Refer to member's Certificate of Coverage or Summary Plan Description.

The following are considered investigative for the treatment of obstructive sleep apnea (see Investigative List): I – XXI

- I. Adjustable tongue-advancement device (eg, Advance system)
- II. Apnea triggered muscle stimulation (does not include hypoglossal nerve stimulation)
- III. Cardiac (Atrial) Pacing
- IV. Cautery-Assisted Palatal Stiffening Operation (CAPSO)
- V. Epiglottidectomy
- VI. Expansion sphincteroplasty
- VII. Flexible Positive Airway Pressure (pressure-relief C-PAP [C-Flex, Respirationics])
- VIII. Genioplasty/genial tubercle advancement
- IX. Glossectomy, partial
- X. Injection Snoreplasty
- XI. Laser assisted Uvuloplasty (LAUP)
- XII. Mandibular distraction osteogenesis (MDO)
- XIII. Nasal dilators
- XIV. Obstructive Sleep Apnea (OSA) oral appliance to restore proper mandibular alignment after use of overnight sleep apnea appliance, for prevention of temporomandibular joint dysfunction (such as, but not limited to, the Direct AM Positioner, Morning Repositioner [SomnoMed])
- XV. Palatal Implants (Pillar Procedure)

Department of Origin: Integrated Healthcare Services	Effective Date: 06/05/24
Approved by: Medical Policy Quality Management Subcommittee	Date Approved: 06/04/24
Clinical Policy Document: Neurostimulation, Hypoglossal Nerve	Replaces Effective Clinical Policy Dated: 12/12/23
Reference #: MC/I012	Page: 3 of 6

- XVI. Provent Sleep Apnea Therapy
- XVII. Radiofrequency Volumetric Tissue Reduction of the palate, tongue, or uvula (Somnoplasty/Coblation)
- XVIII. Remotely controlled mandibular positioner
- XIX. Tongue based reduction surgery
- XX. Tongue Based Suspension (eg, Repose or AIRvance)
- XXI. Winx therapy system/oral pressure therapy

DEFINITIONS:

Apnea:

Transient cessation of respiration

Apnea Hypopnea Index (AHI):

Average number of episodes of *apnea* and/or *hypopnea* per hour of sleep

Malfunctioning:

The failure of a device to meet its performance specifications or otherwise perform as intended. Performance specifications include all claims made in the labeling for the device.

Obstructive Sleep Apnea Types (from AASM):

- *AHI* of 5-14: Mild OSA; Involuntary sleepiness during activities that require little attention (eg, watching TV, reading)
- *AHI* of 15-29: Moderate OSA; Involuntary sleepiness during activities that require some attention (eg, meetings, presentations)
- *AHI* of 30 or greater: Severe OSA; Involuntary sleepiness during activities that require more active attention (eg, talking, driving)

Respiratory Disturbance Index (RDI):

Average number of respiratory disturbances per hour (*apneas*, *hypopneas*, and respiratory event-related arousals [RERAs])

Respiratory Event Index (REI):

Average number of episodes of *apnea* and/or *hypopnea* per total recording time in hours

BACKGROUND:

Obstructive Sleep Apnea (OSA) is a disorder in which complete or partial obstruction of the airway during sleep causes loud snoring, oxyhemoglobin desaturations, and frequent arousals.

Upper airway stimulation is performed using an implanted neurostimulation device that stimulates the hypoglossal nerve to activate the protrusion muscles of the tongue. The patient controls the start and stop times for therapy using a handheld device while the stimulation device gathers information from the sensor throughout therapy to determine the most beneficial time to deliver the stimulation.

Department of Origin: Integrated Healthcare Services	Effective Date: 06/05/24
Approved by: Medical Policy Quality Management Subcommittee	Date Approved: 06/04/24
Clinical Policy Document: Neurostimulation, Hypoglossal Nerve	Replaces Effective Clinical Policy Dated: 12/12/23
Reference #: MC/I012	Page: 4 of 6

Prior Authorization: Yes, per network provider agreement.

CODING:

- 64582 Open implantation of hypoglossal nerve neurostimulator array, pulse generator, and distal respiratory sensor electrode or electrode array
- 64583 Revision or replacement of hypoglossal nerve neurostimulator array and distal respiratory sensor electrode or electrode array, including connection to existing pulse generator

CPT codes copyright 2024 American Medical Association. All Rights Reserved. CPT is a trademark of the AMA. The AMA assumes no liability for the data contained herein.

REFERENCES:

1. Integrated Healthcare Services Process Manual: UR015 Use of Medical Policy and Criteria
2. Clinical Policy: Coverage Determination Guidelines (MP/C009)
3. Clinical Policy: Investigative Services (MP/I001)
4. Clinical Policy: Obstructive Sleep Apnea, Surgical Treatment in Adults (MC/C007)
5. Clinical Policy: Obstructive Sleep Apnea, Non-Surgical Treatment (MC/C011)
6. American Association of Oral and Maxillofacial Surgeons. Obstructive Sleep Apnea. Last updated January 2015. Retrieved from <http://myoms.org/procedures/obstructive-sleep-apnea>. Accessed 04-16-24.
7. American Association of Oral and Maxillofacial Surgeons. Position Paper, Evaluation and Management of Obstructive Sleep Apnea – Overview. 2013. Retrieved from <https://www.aaoms.org/practice-resources/aaoms-advocacy-and-position-statements/white-papers>. Accessed 04-16-24.
8. Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA). Premarket Approval: Inspire Upper Airway Stimulation (UAS). 2014. Retrieved from http://www.accessdata.fda.gov/cdrh_docs/pdf13/P130008a.pdf. Accessed 04-16-24.
9. Epstein LJ, Kristo D, Strollo, Jr. PJ, et al. Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults. 2009. American Academy of Sleep Medicine. *Journal of Clinical Sleep Medicine*, 15(3):263-276. Retrieved from <https://jcsm.aasm.org/doi/10.5664/jcsm.27497>. Accessed 04-16-24.
10. Weaver EM, Kapur VK. Surgical treatment of obstructive sleep apnea in adults. (Topic 97861, Version 28.0; last updated: 04/03/24) In: Finlay G, ed. *UpToDate*. Waltham, MA.: UpToDate; 2020. www.uptodate.com. Accessed 04-16-24.
11. Woodson BT, Soose RJ, Gillespie MB, et al. Three-year outcomes of cranial nerve stimulation for obstructive sleep apnea: The STAR trial. *Otolaryngol Head Neck Surg*. 2016 Jan;154(1):181-8. doi: 10.1177/0194599815616618.
12. Goding GS Jr, Tesfayesus W, Kezirian EJ. Hypoglossal nerve stimulation and airway changes under fluoroscopy. *Otolaryngol Head Neck Surg*. 2012 Jun;146(6):1017-22. doi: 10.1177/0194599812436472. Epub 2012 Feb 3.
13. Chwiesko-Minarowska S, Minarowski L, Kuryliszyn-Moskal A, Chwiesko J, Chyczewska E. Rehabilitation of patients with obstructive sleep apnea syndrome. *Int J Rehabil Res*. 2013 Dec;36(4):291-7. doi: 10.1097/MRR.0b013e3283643d5f.
14. Álvarez D1, Gutiérrez-Tobal GC, Del Campo F, Hornero R. Positive airway pressure and electrical stimulation methods for obstructive sleep apnea treatment: a patent review (2005 - 2014). *Expert Opin Ther Pat*. 2015 Jun 16:1-19. doi: 10.1517/13543776.2015.1054094. Epub 2015 Jun 19.
15. Dedhia RC, Strollo PJ, Soose RJ. Upper Airway Stimulation for Obstructive Sleep Apnea: Past, Present, and Future. *Sleep*. 2015 Jun 1;38(6):899-906. doi: 10.5665/sleep.4736.

Department of Origin: Integrated Healthcare Services	Effective Date: 06/05/24
Approved by: Medical Policy Quality Management Subcommittee	Date Approved: 06/04/24
Clinical Policy Document: Neurostimulation, Hypoglossal Nerve	Replaces Effective Clinical Policy Dated: 12/12/23
Reference #: MC/I012	Page: 5 of 6


16. Woodson BT, Gillespie MB, Soose RJ, et al. Randomized controlled withdrawal study of upper airway stimulation on OSA: short- and long-term effect. *Otolaryngol Head Neck Surg.* 2014 Nov;151(5):880-7. doi: 10.1177/0194599814544445. Epub 2014 Sep 9.
17. Department of Health & Human Services. FDA Approval Letter for AHI Range Expansion. June 23, 2017. Retrieved from <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?ID=404055>.
18. Department of Health & Human Services. FDA Approval Letter for expanding indications to include adolescents patients age 18 to 21. April 14, 2020. Retrieved from <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P130008S039>.
19. US Food and Drug Admin. Code of Federal Regulations Title 21, Volume 8, Subpart A, Sec 803.3, (k) <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm?CFRPart=803&showFR=1>
20. Moskowitz, B. Excessive Sleepiness and Associated Risks with Obstructive Sleep Apnea. OSA: What Role for Hypoglossal Nerve Stimulation? Retrieved from <https://www.medpagetoday.com/resource-centers/excessive-sleepiness-and-associated-risks-with-obstructive-sleep-apnea/osa-role-hypoglossal-nerve-stimulation/2720>. Accessed 04-16-24.
21. Kent D, Stanley J, Aurora N, et al. Referral of adults with obstructive sleep apnea for surgical consultation: an American Academy of Sleep Medicine clinical practice guideline. 2021;17(12). Retrieved from <https://aasm.org/clinical-resources/practice-standards/practice-guidelines/>. Accessed 04-16-24.
22. Suurna M. Hypoglossal nerve stimulation for adult patients with obstructive sleep apnea. (Topic 135053, Version 8.0; last updated: 04-05-24) In: Finlay G, ed. *UpToDate*. Waltham, MA.: UpToDate; 2023. www.uptodate.com. Accessed 04-16-24.
23. Kline LR. Clinical presentation and diagnosis of obstructive sleep apnea in adults. (Topic 7706, Version 65.0; last updated: 10/05/23) In: Finlay G, ed. *UpToDate*. Waltham, MA.: UpToDate; 2023. www.uptodate.com. Accessed 04-16-24.
24. Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA). Premarket Approval: Inspire Upper Airway Stimulation (UAS) Supplement. March 20, 2023. Retrieved from https://www.accessdata.fda.gov/cdrh_docs/pdf13/P130008S089A.pdf. Accessed 04-16-24.
25. Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA). Premarket Approval: Inspire Upper Airway Stimulation (UAS) Supplement. June 8, 2023. https://www.accessdata.fda.gov/cdrh_docs/pdf13/P130008S090A.pdf. Accessed 04-16-24.
26. Paruthi S. Management of obstructive sleep apnea in children. (Topic 6373, Version 50.0; last updated: 04/15/24) In: Hoppin AG, ed. *UpToDate*. Waltham, MA.: UpToDate; 2023. www.uptodate.com. Accessed 04-16-24.
27. US Food and Drug Admin. Summary of Safety and Effectiveness Data (SSED). Implantable Upper Airway Stimulation for Obstructive Sleep Apnea (OSA). 2023. Retrieved from https://www.accessdata.fda.gov/cdrh_docs/pdf13/P130008S090B.pdf. Accessed 04-16-24.

DOCUMENT HISTORY:

Created Date: 05/03/16
Reviewed Date: 04/03/17, 04/03/18, 04/03/19, 03/26/20, 03/26/21, 03/21/22, 03/21/23, 03/20/24
Revised Date: 07/12/17, 03/30/20, 04/22/20, 03/04/21, 09/27/21, 03/31/23, 05/23/23, 10/20/23

Department of Origin: Integrated Healthcare Services	Effective Date: 06/05/24
Approved by: Medical Policy Quality Management Subcommittee	Date Approved: 06/04/24
Clinical Policy Document: Neurostimulation, Hypoglossal Nerve	Replaces Effective Clinical Policy Dated: 12/12/23
Reference #: MC/I012	Page: 6 of 6

Attachment A



Retrieved from MedPage Today: Moskowitz, B. Excessive Sleepiness and Associated Risks with Obstructive Sleep Apnea. OSA: What Role for Hypoglossal Nerve Stimulation?
<https://www.medpagetoday.com/resource-centers/excessive-sleepiness-and-associated-risks-with-obstructive-sleep-apnea/osa-role-hypoglossal-nerve-stimulation/2720>

Nondiscrimination & Language Access Policy

Aspirus Health Plan, Inc. complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, sex, sexual orientation, or gender identity. We do not exclude people or treat them differently because of race, color, national origin, age, disability, sex, sexual orientation, or gender identity.

We will:

Provide free aids and services to people with disabilities to communicate effectively with us, such as:

- Qualified sign language interpreters
- Written information in other formats (large print, audio, accessible electronic formats, other formats)

Provide free language services to people whose primary language is not English, such as:

- Qualified interpreters
- Information written in other languages

If you need these services, contact us at the phone number shown on the inside cover of this contract, your id card, or aspirushealthplan.com.

If you believe that we have failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability, sex, sexual orientation, or gender identity, you can file a grievance with:

Nondiscrimination Grievance Coordinator
Aspirus Health Plan, Inc.
PO Box 1062
Minneapolis, MN 55440
Phone: 1.866.631.5404 (TTY: 711)
Fax: 763.847.4010
Email: customerservice@aspirushealthplan.com

You can file a grievance in person or by mail, fax, or email. If you need help filing a grievance, the Nondiscrimination Grievance Coordinator is available to help you.

You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights, electronically through the Office for Civil Rights Complaint Portal, available at <https://ocrportal.hhs.gov/ocr/portal/lobby.jsf>, or by mail or phone at:

U.S. Department of Health and Human Services
200 Independence Avenue, SW
Room 509F, HHH Building
Washington, D.C. 20201
1-800-368-1019, 800-537-7697 (TDD)

Complaint forms are available at <http://www.hhs.gov/ocr/office/file/index.html>.

Language Assistance Services

Albanian: KUJDES: Nëse flitni shqip, për ju ka në dispozicion shërbime të asistencës gjuhësore, pa pagesë. Telefononi në 1.866.631.5404 (TTY: 711).

Arabic: تنبيه: إذا كنت تتحدث اللغة العربية، فإن خدمات المساعدة اللغوية متاحة لك مجاناً. اتصل بن اعلى رقم الهاتف 1.866.631.5404 (رقم هاتف الصم والبك : 711)

French: ATTENTION : Si vous parlez français, des services d'aide linguistique vous sont proposés gratuitement. Appelezle 1.866.631.5404 (ATS : 711).

German: ACHTUNG: Wenn Sie Deutsch sprechen, stehen Ihnen kostenlos sprachliche Hilfsdienstleistungen zur Verfügung. Rufnummer: 1.866.631.5404 (TTY: 711).

Hindi: _यान द_ : य_द आप िहंदी बोलते ह_ तो आपके िलए मु_त म_ भाषा सहायता सेवाएं उपल_ध ह_। 1.866.631.5404 (TTY: 711) पर कॉल कर_।

Hmong: LUS CEEV: Yog tias koj hais lus Hmoob, cov kev pab txog lus, muaj kev pab dawb rau koj. Hu rau 1.866.631.5404 (TTY: 711).

Korean: 주의: 한국어를 사용하시는 경우, 언어 지원 서비스를 무료로 이용하실 수 있습니다. 1.866.631.5404 (TTY: 711)번으로 전화해 주십시오.

Polish: UWAGA: Jeżeli mówisz po polsku, możesz skorzystać z bezpłatnej pomocy językowej. Zadzwoń pod numer 1.866.631.5404 (TTY: 711).

Russian: ВНИМАНИЕ: Если вы говорите на русском языке, то вам доступны бесплатные услуги перевода. Звоните 1.866.631.5404 (телетайп: 711).

Spanish: ATENCIÓN: si habla español, tiene a su disposición servicios gratuitos de asistencia lingüística. Llame al 1.866.631.5404 (TTY: 711).

Tagalog: PAUNAWA: Kung nagsasalita ka ng Tagalog, maaari kang gumamit ng mga serbisyo ng tulong sa wika nangwalang bayad. Tumawag sa 1.866.631.5404 (TTY: 711)

Traditional Chinese: 注意: 如果您使用繁體中文, 您可以免費獲得語言援助服務。請致電 1.866.631.5404 (TTY:711)。

Vietnamese: CHÚ Ý: Nếu bạn nói Tiếng Việt, có các dịch vụ hỗ trợ ngôn ngữ miễn phí dành cho bạn. Gọi số 1.866.631.5404 (TTY: 711).

Pennsylvania Dutch: Wann du Deitsch (Pennsylvania German / Dutch) schwetzsch, kannscht du mitaus Koschte ebbergricke, ass dihr helft mit die englisch Schprooch. Ruf selli Nummer uff: Call 1.866.631.5404 (TTY: 711).

Lao: ໄປດຊາຍ: ຖ້າວ່າ ທ່ານເວົ້າພາສາ ລາວ, ການບໍລິການຊ່ວຍເຫຼືອດ້ານພາສາ, ໂດຍບໍ່ເສັຽຄ່າ, ແມ່ນມີພ້ອມໃຫ້ທ່ານ. ໂທ 1.866.631.5404 (TTY:711).